Intravitreal injection of bevacizumab for cystoid macular edema in retinitis pigmentosa

Melo, Gustavo Barreto; Farah, Michel Eid; Aggio, Fábio Bom

doi:10.1111/j.1600-0420.2006.00872.x

Cited by 41 publications

(25 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bevacizumab (AvastinÔ; Genentech, Inc., South San Francisco, CA, USA), originally developed to treat metastatic carcinoma of the colon and rectum, is a full-length recombinant humanized monoclonal antibody to all VEGF isoforms. Recent studies have reported the usefulness of an intravitreal injection of bevacizumab in causing regression of choroidal and iris neovascularization (Oshima et al 2006;Gomi et al 2007;Sakaguchi et al 2007), proliferative diabetic retinopathy (Tonello et al 2007) and macular oedema caused by central retinal vein occlusion (Spandau et al 2006), as well as in retinitis pigmentosa (Melo et al 2007).…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema

Fang

Sakaguchi

Gomi

et al. 2008

Acta Ophthalmologica

View full text Add to dashboard Cite

ABSTRACT.Purpose: To assess the efficacy, duration of effect and safety of one intravitreal injection of bevacizumab in diabetic macular oedema (DMO). Methods: Bevacizumab (1 mg ⁄ 0.04 ml) was injected intravitreally into eyes with DMO (29 with and nine without previous treatments). Best corrected visual acuity (BCVA), intraocular pressure and central retinal thickness (CRT) were measured; slit-lamp examination, macular biomicroscopy, optical coherence tomography and fluorescein angiography were performed before and at 2-4, 8 and 12 weeks post-injection. Best corrected VA and CRT were analysed in both groups. Results: In the non-pretreated group, mean BCVA improved from 0.76 ± 0.33 (baseline) to 0.57 ± 0.30 and 0.54 ± 0.27 at 2-4 weeks and 8 weeks postinjection, respectively (p = 0.02, p = 0.014, paired t-test). Mean CRT decreased from 632.4 ± 196.0 lm (baseline) to 392.3 ± 113.6 lm and 370.4 ± 141.7 lm at the same time-points, respectively (p = 0.01, p = 0.01). There was no difference in BCVA or CRT at 12 weeks. In the pretreated group, mean BCVA improved from 0.62 ± 0.30 (baseline) to 0.53 ± 0.33 at 2-4 weeks post-injection (p = 0.01), and mean CRT decreased from 583.9 ± 180.7 lm (baseline) to 404.1 ± 197.9 lm at 2-4 weeks post-injection (p < 0.001). Mean BCVA was unchanged at 8 weeks and 12 weeks postinjection, although mean CRT remained lower at 8 weeks (p = 0.004). No ocular or systemic side-effects developed during follow-up. Conclusions: One intravitreal injection of bevacizumab for DMO seems to be effective and safe in both eyes that have been treated previously and eyes that have not. The therapeutic effect is temporary and repeat treatment may be needed.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema

Fang

Sakaguchi

Gomi

et al. 2008

Acta Ophthalmologica

View full text Add to dashboard Cite

show abstract

“…Several therapies are used to treat CME in RP patients and include topical or oral administration of carbonic anhydrase inhibitor, [1][2][3][4] periocular or intravitreal injection of steroid, [5][6][7][8][9] intravitreal injection of bevacizumab, 10 photocoagulation, 11,12 or vitrectomy. 13 Although each of these therapeutic measures provides a benefit for some of the patients, there is little information on the pathophysiology, prevalence, or natural course of CME that is associated with RP.…”

Section: Introductionmentioning

confidence: 99%

Photoreceptor integrity and visual acuity in cystoid macular oedema associated with retinitis pigmentosa

Oishi

Otani

Sasahara

et al. 2008

Eye

View full text Add to dashboard Cite

Aims To assess the correlation between macular morphology and visual acuity in retinitis pigmentosa (RP) patients with cystoid macular oedema (CME). Design Retrospective cross-sectional study. Patients and methods Forty-one eyes of 25 RP patients with CME. Patients underwent cross-sectional scans with optical coherence tomography (Stratus OCT). Age, total retinal thickness, photoreceptor thickness, and the transverse and vertical lengths of the cystoid space were measured. Correlation between visual acuity and each of the measurements were examined. Additionally, the status of the inner segment/outer segment junction (IS/OS) was classified as being absent, discontinuous, or distinct. Measurements were then compared among the three groups. Results Total retinal thickness or photoreceptor thickness was not correlated with visual acuity. There was a correlation between the transverse length of the cystoid space and visual acuity, although the correlation coefficient was weak (r ¼ 0.30). The logMAR visual acuity in the IS/OS absent group (0.67±0.43) was worse than that seen in the IS/OS discontinuous (0.22 ± 0.19) or IS/OS distinct groups (0.07 ± 0.16) (Po0.001). Conclusions When monitoring CME associated with RP, the status of IS/OS is the essential parameter that needs to be examined.

show abstract

“…Several recent studies have reported the effects of bevacizumab on different ocular cells, including choroidal endothelial cells (Spandau et al 2006;Spitzer et al 2006;Kernt et al 2008;Melo et al 2007;Minnella et al 2007;Pedersen et al 2007;Soliman et al 2008;Yoeruek et al 2008). However, none of these papers explored the effect of this anti-VEGF molecule on the various steps of the angiogenic process, such as the ability of endothelial cells to proliferate, prevent apoptosis, migrate and differentiate into tubules.…”

Section: Discussionmentioning

confidence: 99%

Multiple effects of bevacizumab in angiogenesis: implications for its use in age‐related macular degeneration

Carneiro

Falcão

Azevedo

et al. 2009

Acta Ophthalmologica

View full text Add to dashboard Cite

ABSTRACT.Purpose: This study aimed to elucidate the precise effects of bevacizumab in all steps in the neovascularization process in endothelial cells. Methods: Human umbilical vein endothelial cells (HUVECs) were incubated with bevacizumab at concentrations within the clinically established range or with identical amounts of excipient. Cell cytotoxicity (evaluated by MTT assay), proliferation (by BrdU incorporation assay), apoptosis (by TUNEL assay), migration (by double-chamber assay) and vessel assembly in matrigelcoated plates were assessed in vitro. Mouse plug matrigel assays were performed to confirm in vitro results. Results: Incubation of HUVECs with bevacizumab did not present cytotoxicity. Concentrations comparable with those after intravitreal doses of bevacizumab significantly reduced proliferation and migration capacity, and increased apoptotic rates in these cells. In addition, bevacizumab led to a significant decrease in the assembly of capillary-like structures on matrigel assay in comparison with excipient-treated cells. Further substantiating these in vitro findings, bevacizumab also inhibited angiogenesis in a mouse plug matrigel assay, as evaluated by haemoglobin content levels.Conclusions: These results demonstrate that clinical doses of bevacizumab are able to prevent several steps of the angiogenic process. Bevacizumab is thus currently recommended for treating disorders that present augmented angiogenesis.

show abstract

Intravitreal injection of bevacizumab for cystoid macular edema in retinitis pigmentosa

Cited by 41 publications

References 5 publications

Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema

Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema

Photoreceptor integrity and visual acuity in cystoid macular oedema associated with retinitis pigmentosa

Multiple effects of bevacizumab in angiogenesis: implications for its use in age‐related macular degeneration

Contact Info

Product

Resources

About